AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04458181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Peer Journaling (PPJ)
Description: PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health.
Study NCT02081118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
Study NCT03579628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue.
Study NCT04097197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief educational intervention
Description: same as before
Study NCT03969264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Carbohydrate or Tree Nut Food Snacks
Description: Snack consumption
Study NCT03969264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate or Tree Nut Food Snacks
Description: Snack consumption
Study NCT02972333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80mg oral each day
Description: All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
Study NCT02972333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
Study NCT02081118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for HM11260C
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV solution
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV solution
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablet
Study NCT00931918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet
Study NCT02694796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program after a balneotherapy
Description: workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
Study NCT01781013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-supported care
Description: The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
Study NCT01219777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study NCT01219777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study NCT01219777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study NCT03690921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03690921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03690921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Description: Undergo LET-IMPT
Study NCT03690921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03690921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00586118 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
Study NCT00586118 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
Study NCT03453203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic Manipulative Treatment Using Counterstrain
Description: Described in arm/group descriptions
Study NCT03453203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic Manipulative Treatment Using Counterstrain
Description: Described in arm/group descriptions
Study NCT02606383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole
Study NCT02606383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Study NCT02003378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker sensor set to MV
Description: Pacemaker sensor set to minute ventilation
Study NCT02003378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker sensor set to XL
Description: Pacemaker sensor set to accelerometer
Study NCT03228277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmutinib
Description: Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
Study NCT01753596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)
Study NCT01753596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Sodium Chloride solution (0,9%)
Description: Placebo
Study NCT02633566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plantar orthoses
Study NCT02633566 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plantar orthoses
Study NCT02959177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT02959177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00443677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPPEBVCAD vs BEACOPP vs ABVD
Study NCT00443677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPPEBVCAD vs BEACOPP vs ABVD
Study NCT01327027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine, ADH
Description: Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
Study NCT01327027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Sterile Saline
Description: Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
Study NCT03630692 — intervention group
Intervention type: DRUG
Intervention: observance of oral drug treatment
Description: Completion of questionnaires at 4 times during patient's oral route drug treatment
Study NCT02921139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Description: Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
Study NCT02921139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-Transcatheter arterial chemoembolization (re-TACE)
Description: Patients with HCC after incomplete TACE are randomized to further re-TACE.
Study NCT02209727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-Sibrotuzumab
Description: 50 mg Sibrotuzumab conjugated with 131I
Study NCT00781417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 50,000 IU once a week for 12 weeks then every other week for 40 weeks
Study NCT05331781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transversus Abdominis Plane Block
Description: patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
Study NCT05331781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
Study NCT00781417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01274559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Description: 1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
Study NCT01274559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
Study NCT02219776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide solution Plus Chlorhexidine Scrub
Description: Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
Study NCT02219776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Chlorhexidine Scrub only
Description: Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
Study NCT01359618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose, oral encapsulated tablet
Study NCT01359618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo comparator
Description: Single dose, oral encapsulated tablet
Study NCT03383952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICAR19 CAR-T cells
Description: T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Study NCT01190111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
Study NCT04405622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus gemcitabine
Description: Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study NCT03309826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Auto-PAP titration followed by fixed PAP treatment
Study NCT03309826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Dilator Strip
Description: Nightly use of nasal dilator strip
Study NCT03376217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPTp delivered by HSAs
Description: Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
Study NCT04373798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: Measurement of CRP value from blood sample taken at covid19 check point (baseline).
Study NCT00803205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Study NCT00803205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ataluren will be provided.
Study NCT01944826 — intervention group
Intervention type: OTHER
Intervention: Registry of patients with Tako-Tsubo cardiomyopathy
Study NCT04302480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksheets for ASP
Description: The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
Study NCT04302480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Worksheets for SSB
Description: The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
Study NCT04302480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-messages for ASP
Description: In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
Study NCT04302480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-messages for SSB
Description: In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
Study NCT04202289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nile Tilapia Fish Skin
Description: In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
Study NCT04202289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine Cream 1%
Description: Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
Study NCT00181649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human prolactin
Study NCT03140956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.
Study NCT03140956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa, carbidopa, ODM-104
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.
Study NCT04733716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using Tourniquet
Description: The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
Study NCT01057797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-specific self-efficacy
Description: Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
Study NCT01057797 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gentle chair exercise
Description: Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
Study NCT01057797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: upper body strength training
Description: 16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.